A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

December 5, 2022

Primary Completion Date

December 17, 2024

Study Completion Date

December 17, 2024

Conditions
Chronic Heart Failure
Interventions
DRUG

mRNA-0184

mRNA-0184 dispersion for intravenous (IV) infusion

DRUG

Placebo

0.9% sodium chloride (normal saline) injection

Trial Locations (14)

32216

Jacksonville Center For Clinical Research - ERN - PPDS, Jacksonville

32608

University of Florida, Gainesville

35211

Cardiology PC, Birmingham

35233

University of Alabama at Birmingham: The Kirklin Clinic, Birmingham

37388

Tennessee Center for Clinical Trials, Tullahoma

61-848

Uniwersytecki Szpital Kliniczny w Poznaniu, Poznan

50-556

Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego we Wroclawiu, Wroclaw

15-276

Uniwersytecki Szpital Kliniczny w Bialymstoku, Bialystok

40-635

Gornoslaskie Centrum Medyczne im. prof. Leszka Gieca Slasiego Uniwersytetu Medycznego w Katowicach, Katowice

DD1 9SY

Ninewells Hospital & Medical School, Dundee

CB2 0QQ

Addenbrooke's Hospital, Cambridge

NW1 2BU

University College Hospital, London

PL6 8DH

Derriford Hospital, Plymouth

L7 8XP

The Royal Liverpool University Hospital, Liverpool

All Listed Sponsors
lead

ModernaTX, Inc.

INDUSTRY